Alnylam Pharmaceuticals | ALNY - Ebitda


Alnylam Pharmaceuticals reported $245.34M in EBITDA for its fiscal quarter ending in June of 2026.





Ebitda Change Date
Acadia Pharmaceuticals USD -1.62M 21.94M Mar/2026
Agios Pharmaceuticals USD -108.66M 11.65M Mar/2026
Alnylam Pharmaceuticals USD 245.34M 59.15M Jun/2026
Amgen USD 3.86B 1.28B Mar/2026
Arrowhead Research USD -147.68M 40.33M Jun/2026
BioCryst Pharmaceuticals USD 51.7M 30.14M Sep/2025
BioMarin Pharmaceutical USD 146.05M 170.22M Mar/2026
Incyte USD 778.57M 410.6M Jun/2026
Ionis Pharmaceuticals USD -64.53M 135.49M Mar/2026
Moderna USD -1.26B 468M Mar/2026
Neurocrine Biosciences USD 193.3M 25.1M Mar/2026
Novartis USD 5.41B 431M Mar/2026
PTC Therapeutics USD 61.98M 132.97M Mar/2026
Regeneron Pharmaceuticals USD 1.66B 695.2M Jun/2026
Sanofi EUR 2.72B 2.94B Mar/2026
Sarepta Therapeutics USD 375.48M 627.68M Mar/2026
Takeda JPY 364.46B 214.21B Jun/2026
Tectonic Therapeutic USD -21.18M 365K Dec/2025
Ultragenyx Pharmaceutical USD -155M 55.57M Mar/2026
Vertex Pharmaceuticals USD 1.33B 130.5M Jun/2026
Xencor USD -34.63M 86.74M Jun/2026